GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum-Si Inc (NAS:QSI) » Definitions » ROCE %

Quantum-Si (Quantum-Si) ROCE % : -33.72% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Quantum-Si ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Quantum-Si's annualized ROCE % for the quarter that ended in Mar. 2024 was -33.72%.


Quantum-Si ROCE % Historical Data

The historical data trend for Quantum-Si's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum-Si ROCE % Chart

Quantum-Si Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
- -96.74 -35.87 -30.53 -28.97

Quantum-Si Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.99 -31.37 -34.07 -17.07 -33.72

Quantum-Si ROCE % Calculation

Quantum-Si's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-95.96/( ( (391.485 - 15.706) + (298.25 - 11.609) )/ 2 )
=-95.96/( (375.779+286.641)/ 2 )
=-95.96/331.21
=-28.97 %

Quantum-Si's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-93.44/( ( (298.25 - 11.609) + (275.585 - 7.972) )/ 2 )
=-93.44/( ( 286.641 + 267.613 )/ 2 )
=-93.44/277.127
=-33.72 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum-Si  (NAS:QSI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Quantum-Si ROCE % Related Terms

Thank you for viewing the detailed overview of Quantum-Si's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum-Si (Quantum-Si) Business Description

Traded in Other Exchanges
N/A
Address
530 Old Whitfield Street, Guilford, CT, USA
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
Executives
Amir Jafri director C/O QUANTUM-SI INCORPORATED, 29 BUSINESS PARK DR., BRANFORD CT 06405
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jeffry R. Keyes officer: Chief Financial Officer 13950 STOWE DRIVE, POWAY CA 92064-8803
Scott Mendel director 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Christian Lapointe officer: General Counsel & Corp. Secr. C/O QUANTUM-SI INCORPORATED, 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Grace Johnston officer: Chief Commercial Officer C/O QUANTUM-SI INCORPORATED, 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Kevin Rakin director, officer: Chairman and CEO 36 CHURCH LANE, WESTPORT CT 06880
Jeffrey Alan Hawkins director, officer: Chief Executive Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Vikram Bajaj director 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Jonathan M Rothberg director, 10 percent owner C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD ST., GUILFORD CT 06437
Matthew Dyer officer: Chief Business Officer C/O QUANTUM-SI INCORPORATED, 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Michael P Mckenna officer: President and COO C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Patrick Schneider officer: President and COO C/O QUANTUM-SI INCORPORATED, 530 OLD WHITFIELD STREET, GUILFORD CT 06437
John Viii Stark director, officer: Chief Executive Officer C/O QUANTUM-SI INCORPORATED, 530 OLD WHITFIELD STREET, GUILFORD CT 06437
2012 Jmr Trust Common Llc 10 percent owner C/O QUANTUM-SI INCORPORATED, 530 OLD WHITFIELD STREET, GUILFORD CT 06437